These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action. Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331 [TBL] [Abstract][Full Text] [Related]
7. Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs. Coëffier E; Borrel MC; Lefort J; Chignard M; Broquet C; Heymans F; Godfroid JJ; Vargaftig BB Eur J Pharmacol; 1986 Nov; 131(2-3):179-88. PubMed ID: 3816952 [TBL] [Abstract][Full Text] [Related]
8. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Alabaster VA; Keir RF; Parry MJ; de Souza RN Agents Actions Suppl; 1991; 34():221-7. PubMed ID: 1793066 [TBL] [Abstract][Full Text] [Related]
9. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914 [TBL] [Abstract][Full Text] [Related]
10. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188 [TBL] [Abstract][Full Text] [Related]
11. N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents. Tilley JW; Levitan P; Lind J; Welton AF; Crowley HJ; Tobias LD; O'Donnell M J Med Chem; 1987 Jan; 30(1):185-93. PubMed ID: 2879917 [TBL] [Abstract][Full Text] [Related]
12. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine. Fray MJ; Bull DJ; Cooper K; Parry MJ; Stefaniak MH J Med Chem; 1995 Sep; 38(18):3524-35. PubMed ID: 7658439 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. Paris D; Cottin M; Demonchaux P; Augert G; Dupassieux P; Lenoir P; Peck MJ; Jasserand D J Med Chem; 1995 Feb; 38(4):669-85. PubMed ID: 7861415 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029 [TBL] [Abstract][Full Text] [Related]
17. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Hwang SB; Li CL; Lam MH; Shen TY Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. Casals-Stenzel J; Muacevic G; Weber KH J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913 [TBL] [Abstract][Full Text] [Related]
19. 2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel orally active antagonists of platelet-activating factor (PAF). Nagaoka H; Hara H; Suzuki T; Takahashi T; Takeuchi M; Matsuhisa A; Saito M; Yamada T; Tomioka K; Mase T Chem Pharm Bull (Tokyo); 1997 Oct; 45(10):1659-64. PubMed ID: 9353894 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis. Sakuma Y; Shirato M; Nagaoka J; Obaishi H; Tsunoda H; Katayama S; Ono H; Katayama K Arzneimittelforschung; 1991 Dec; 41(12):1255-9. PubMed ID: 1815526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]